RTTNews BiotechDoubao · 实盘不做把握 7/10不做原因:无增量信息
北京时间·🕒 发布 19:46:38·⟳ 抓取 20:00:20 +13m42s·⚡ 决策 10-12 20:02:28 +2m08s·15.2 天前
ANI制药公布ILUVIEN葡萄膜炎IV期SYNCHRONICITY试验两年期视力改善数据，为已上市产品旧数据的学术更新
这是一个已获批产品的IV期（上市后确认性）试验学术展示，核心阳性结果（6个月双主要终点）早在2026年7月13日公司新闻稿中公布，9月30日又预先告知AAO报告；本次24个月数据只是疗效维持的次要终点，安全性格局与既往一致，未带来新适应症、标签变化、订单或指引上调。叠加ILUVIEN收入占比很小（Q1 2026约1930万美元，对比公司2026年约11亿美元总收入指引），缺乏短线正edge，属于低增量、可预期的旧闻更新，不做。
📄 原文RTTNews Biotech↗ 原文
ANI Pharmaceuticals Report Two-Year Vision Improvements In Phase 4 Eye Disease Study
Business Business Latest Headlines Top Stories Breaking News Earnings Biotech Investors Stock Alerts IPOs M&A Canadian…
不做 ANI Pharmaceuticals（ANIP.US）
无增量事实：ILUVIEN为已上市产品，SYNCHRONICITY IV期6个月阳性主要终点已于2026-07-13披露、9月30日预告AAO展示，10月12日仅为24个月维持数据的会议复述，无新标签/适应症/指引；且ILUVIEN Q1 2026收入仅约1930万美元、占公司收入比重低，缺乏短线正edge与materiality，不追。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
ANIP的ILUVIEN IV期SYNCHRONICITY试验24个月维持数据正面，但6个月主要终点阳性已于2026年7月披露、9月预告AAO展示，本次无新标签/新适应症/指引变化，且ILUVIEN收入占比低（Q1仅约1930万美元），增量信息与materiality均不足，AVOID。
消息传播链
- RTTNews复述AAO口头报告：疗效维持至24个月、安全性与既往一致；无新监管/商业信息，属会议数据的媒体扩散。
关键理由
- 数据本身方向正面且已在AAO 2026 late-breaking口头报告展示，但属于已上市、已获批该适应症产品的IV期确认性试验随访，无监管或商业状态迁移。
- 核心阳性结论（6个月BCVA/CST双主要终点达成）公司已于2026-07-13新闻稿公布，市场对该试验成功早有定价，24个月维持数据为低增量更新。
主要风险
- 若市场把AAO高规格展示与24个月耐久性数据解读为新的处方推广催化剂，可能带来情绪性小幅反弹，但缺乏收入量级支撑，追高风险大于edge。
- 单一开放标签单臂108人小样本、无新增安全性信号，本次不会改变临床指南或竞品格局。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-12 · 影响 weakens
未发现随本次AAO数据公布的新适应症、标签扩展、商业合作或指引上调；ILUVIEN葡萄膜炎适应症此前已获批，本次仅补充证据，削弱LONG edge。
检索:ANI Pharmaceuticals ILUVIEN label expansion approval uveitis 2026 new catalyst guidance 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不改变结论；AVOID基于事件本身增量不足，而非价格先例。
方向:未使用先例：本事件在决策前已因'无增量事实（IV期随访旧数据）+低materiality'判定AVOID，无需用同类临床数据事件的涨幅校准止盈止损。
涨幅量级:不适用，无ENTER腿。
形态:不适用；已上市产品IV期学术更新通常不构成可交易催化，但本次未据此量化。
工具执行结果 · 成功 6 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 11 ms
{"result": "search_processed_events:agent query=`ani pharmaceuticals anip synchronicity phase 4 fluocinolone acetonide iluvien uveitis 24-month two-year results | anip iluvien chronic niu-ps six-month co-primary endpoints aao 202`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agen - web_search 成功 doubao_search · 4,530 ms
web_search「ANI Pharmaceuticals SYNCHRONICITY Phase 4 fluocinolone acetonide uveitis six-month positive data press release」无结果。 - web_search 成功 doubao_search · 2,926 ms
豆包搜索结果（原始查询:ANI Pharmaceuticals ILUVIEN revenue contribution 2025 net sales uveitis；API SearchType:web） - web_search 成功 doubao_search · 1,891 ms
豆包搜索结果（原始查询:ANI Pharmaceuticals "SYNCHRONICITY" ILUVIEN six-month results 2026 announcement；API SearchType:web） - web_search 成功 doubao_search · 1,863 ms
豆包搜索结果（原始查询:ANI Pharmaceuticals ILUVIEN YUTIQ net sales 2025 ophthalmology segment revenue million；API SearchType:web） - web_search 成功 doubao_search · 2,709 ms
豆包搜索结果（原始查询:"ILUVIEN" net revenues first quarter 2026 ANI Pharmaceuticals million；API SearchType:web）
原文全文
展开原文 · 9,108 字
ANI Pharmaceuticals Report Two-Year Vision Improvements In Phase 4 Eye Disease Study
Business
Business
Latest Headlines
Top Stories
Breaking News
Earnings
Biotech
Investors
Stock Alerts
IPOs
M&A
Canadian
UK
Wallstreet Events
Industry News
Industry News
Technology
Software
Banking
Automotive
Energy
More
Corp. Calendars
Dividends
Stock Splits
Buybacks
Conference Calls
Earnings Calendar
Earnings Calendar
Pos Pre-announcements
Profit Warnings
Positive Surprise
Negative Surprise
Latest Earnings
FDA Calendars
Drug Approvals
Clinical Trial Calendar
Ratings Changes
Upgrades
Downgrades
Cov Initiations
Cov. Reiterated
Economy
Economic News
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard
Cryptocurrency
Crypto
Cryptocurrency
Blockchain
Markets
Markets
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies
Politics
Politics
US
World
White House
Elections
General News
Forex
Forex
FX Top Stories
Currency Analysis
Currency Alerts
Economic Calendar
Economic Scorecard
Health
Health
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health
Slide Shows
Entertainment
Entertainment
Top Stories
Music news
Pop
Rock
Classic Rock
Rap/Hip-Hop
Country
Alternative
Oldies
All Genre
Content Licensing
Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services
Premium Services
Premium
Intelligent Investor
Biotech Investor
NEW
Login
More
Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us
Biotech Daily Dose
ANI Pharmaceuticals Report Two-Year Vision Improvements In Phase 4 Eye Disease Study
By
TajSabreen Ahamed
✉
Published:
10/12/2026 7:46 AM ET
Follow Us
Join Us
Add
as your preferred news source on Google
Add Now
ANI Pharmaceuticals (
ANIP
) announced positive results from its Phase 4 SYNCHRONICITY trial evaluating the Fluocinolone Acetonide Intravitreal Implant in patients with chronic non-infectious uveitis affecting the posterior segment of the eye (chronic NIU-PS).
The findings were presented in a late-breaking oral presentation at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting.
Chronic non-infectious uveitis affecting the back of the eye is a serious inflammatory condition that can lead to vision loss if left untreated. Managing inflammation and preserving vision are key treatment goals for these patients.
The Phase 4 SYNCHRONICITY study enrolled 108 patients and evaluated the Fluocinolone Acetonide Intravitreal Implant in a real-world clinical setting. The trial met both of its co-primary endpoints at six months, demonstrating statistically significant improvements in best-corrected visual acuity (BCVA), a measure of vision, and reductions in central subfield thickness (CST), a marker of retinal swelling.
According to the data presented, these improvements were maintained through 24 months, a key secondary endpoint of the study.
The study's safety findings were consistent with previous clinical experience with the fluocinolone acetonide implant. The most commonly reported adverse events were similar to those observed in earlier trials of the treatment.
ILUVIEN is a sustained-release corticosteroid implant that delivers fluocinolone acetonide directly into the eye for up to 36 months. In the United States, it is approved for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye and diabetic macular edema in certain previously treated patients.
The implant is designed to provide long-term corticosteroid treatment directly inside the eye to help control inflammation associated with chronic uveitis and other retinal diseases.
ANI said the results add to the growing body of evidence supporting the use of the implant in patients with chronic NIU-PS, including those treated by retina specialists in routine clinical practice.
ANIP has traded in a 52-week range of $69.58 to $97.00. The stock closed Friday's trading (October 9, 2026) at $73.89, up 2.65%.
For comments and feedback contact: editorial@rttnews.com
Business News
Slide Shows
Biotech Stocks Facing FDA Decision In October 2026
Biotech Stocks Facing FDA Decision In September 2026
Biotech Stocks Facing FDA Decision In August 2026
Latest Updates on Middle East War
Sen. Murphy Says Hegseth Covering Up Cost And Damages Of Iran War
October 09, 2026 07:35 ET
Crude Oil Prices Moderately Higher After Yesterday's Spike
October 09, 2026 14:44 ET
U.S. Stocks Close Mostly Lower On Spike In Oil Prices, OpenAI Revenue Concerns
October 08, 2026 16:17 ET
U.S. Stocks Mostly Lower As Crude Oil Prices Spike
October 08, 2026 11:19 ET
Renewed Spike In Crude Oil Prices May Weigh On Wall Street
October 08, 2026 08:50 ET
View More
The minutes of the latest Federal Reserve policy session was the highlight this week which saw relatively less news on the economics front in the U.S. Latest trade data and survey results on the priva
October 09, 2026 15:35 ET
The minutes of the latest Federal Reserve policy session was the highlight this week which saw relatively less news on the economics front in the U.S. Latest trade data and survey results on the private sector also gained attention. In Europe, results of the purchasing managers’ survey were in focus, while the Reserve Bank of India policy announcement took the center stage in Asia.
View More Videos
RELATED NEWS
ANI Pharmaceuticals Wins FDA Approval For Generic Everolimus Tablets For Oral Suspension
FDA Approves ANI Pharma's Generic Everolimus Tablets
ANI Pharmaceuticals, Inc. Profit Climbs In Q2
ANI Pharmaceuticals Reports Positive Six-Month Data In Uveitis Trial
ANI Pharma Reports Positive Phase 4 Data For Fluocinolone Acetonide Implant In Chronic Uveitis
Latest Updates on COVID-19
View More
Editor's Pick
Most Read
Most Emailed
Delta Stock Drops On Cautious Earnings View In Q4 & FY26 After Weak Q3
October 09, 2026 09:40 ET
Nvidia-backed Australian AI Firm Firmus Scraps IPO Over Market Conditions
October 09, 2026 07:54 ET
American Airlines To Expand Starlink Connectivity To More Than 1000 Mainline Aircraft
October 08, 2026 11:57 ET
PepsiCo Q3 Profit Climbs, Core Margin Down; Updates FY26 View; Stock Gains
October 08, 2026 08:12 ET
Tesco Plc Stock Gains On H1 Profit Growth, FY27 Outlook Upgrade, Addl. Buyback
October 08, 2026 05:39 ET
Alimentation Couche-Tard To Buy Irving Oil Retail Assets In Québec, Ontario
October 09, 2026 10:19 ET
PepsiCo Q3 Profit Climbs, Core Margin Down; Updates FY26 View; Stock Gains
October 08, 2026 08:12 ET
Delta Stock Drops On Cautious Earnings View In Q4 & FY26 After Weak Q3
October 09, 2026 09:40 ET
Verizon, AT&T And T-Mobile Shares Plunge As SpaceX Strikes Spectrum Deal To Expand Starlink Mobile
October 09, 2026 17:32 ET
Nvidia-backed Australian AI Firm Firmus Scraps IPO Over Market Conditions
October 09, 2026 07:54 ET
Crescent Energy To Buy Devon's Eagle Ford Assets For $3.85 Bln; Launches $1 Bln Stock Offering
October 08, 2026 07:53 ET
DCC Energy Agrees To Sell Nexora To One Equity Partners For $725 Mln
October 09, 2026 02:30 ET
Hexagon To Buy Rocscience For $535 Mln
October 09, 2026 02:46 ET
Starbucks Explores Takeover Of Chipotle In Potential Record Restaurant Deal
October 08, 2026 17:01 ET
Fairfax Financial To Partner With Wittington To Acquire Boots Group
October 07, 2026 09:49 ET
Microchip Technology Acquires VORAGO Technologies For Undisclosed Sum
October 09, 2026 09:14 ET
Natera's Multi-cancer Early Detection Assay Granted Breakthrough Device Designation By FDA
October 09, 2026 08:17 ET
Netflix Reportedly Plans To Lay Off 5% Of Its Workforce
October 09, 2026 11:17 ET
LG Electronics Q3 Prelim. Operating Income, Revenues Rise; Stock Drops
October 07, 2026 00:57 ET
Teva Pharmaceutical Stock Rises 6% After FDA Approves Monthly Schizophrenia Treatment
October 09, 2026 11:24 ET
Waystream Group Q3 Sales Increase
October 07, 2026 01:14 ET
Alignment Healthcare Stock Falls 17% On 2027 Medicare Star Ratings
October 09, 2026 11:26 ET
Intact Financial Projects Total Pre-tax Catastrophe Losses Of About C$660 Mln In Q3
October 07, 2026 01:15 ET
Toro Slips To Loss In Q2, Shares Down By Over 14%
October 09, 2026 12:02 ET
Ballard Secures 4.8MW Order From Siemens Mobility To Power Romanian Hydrogen Trains
October 07, 2026 01:39 ET
VEON's Banglalink Launches Starlink Satellite-to-mobile In Bangladesh
October 09, 2026 12:12 ET
Lunnon Metals Notes BHP Deal To Sell Kambalda Nickel Concentrator To Gold Fields
October 07, 2026 01:43 ET
Avient Stock Falls 5% After Appointing Mike Frank As CEO
October 09, 2026 12:33 ET
Netcall PLC Profit Falls In Full Year
October 07, 2026 02:09 ET
Editors Pick
Delta Stock Drops On Cautious Earnings View In Q4 & FY26 After Weak Q3
October 09, 2026 09:40 ET
PepsiCo Q3 Profit Climbs, Core Margin Down; Updates FY26 View; Stock Gains
October 08, 2026 08:12 ET
Tesco Plc Stock Gains On H1 Profit Growth, FY27 Outlook Upgrade, Addl. Buyback
October 08, 2026 05:39 ET
Walmart Recalls Over 4.4 Mln Grill Brushes For Ingestion Risk
October 02, 2026 09:11 ET
Loading...
Business
Business
Latest Headlines
Top Stories
Breaking News
Earnings
Biotech
Investors
Stock Alerts
IPOs
M&A
Canadian
UK
Wallstreet Events
Industry News
Industry News
Technology
Software
Banking
Automotive
Energy
More
Corp. Calendars
Dividends
Stock Splits
Buybacks
Conference Calls
Earnings Calendar
Earnings Calendar
Pos Pre-announcements
Profit Warnings
Positive Surprise
Negative Surprise
Latest Earnings
FDA Calendars
Drug Approvals
Clinical Trial Calendar
Ratings Changes
Upgrades
Downgrades
Cov Initiations
Cov. Reiterated
Economy
Economic News
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard
Cryptocurrency
Crypto
Cryptocurrency
Blockchain
Markets
Markets
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies
Politics
Politics
US
World
White House
Elections
General News
Forex
Forex
FX Top Stories
Currency Analysis
Currency Alerts
Economic Calendar
Economic Scorecard
Health
Health
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health
Slide Shows
Entertainment
Entertainment
Top Stories
Music news
Pop
Rock
Classic Rock
Rap/Hip-Hop
Country
Alternative
Oldies
All Genre
Content Licensing
Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services
Premium Services
Premium
Intelligent Investor
Biotech Investor
NEW
Login
More
Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us
Biotech Daily Dose
ANI Pharmaceuticals Report Two-Year Vision Improvements In Phase 4 Eye Disease Study
By
TajSabreen Ahamed
✉
Published:
10/12/2026 7:46 AM ET
Follow Us
Join Us
Add
as your preferred news source on Google
Add Now
ANI Pharmaceuticals (
ANIP
) announced positive results from its Phase 4 SYNCHRONICITY trial evaluating the Fluocinolone Acetonide Intravitreal Implant in patients with chronic non-infectious uveitis affecting the posterior segment of the eye (chronic NIU-PS).
The findings were presented in a late-breaking oral presentation at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting.
Chronic non-infectious uveitis affecting the back of the eye is a serious inflammatory condition that can lead to vision loss if left untreated. Managing inflammation and preserving vision are key treatment goals for these patients.
The Phase 4 SYNCHRONICITY study enrolled 108 patients and evaluated the Fluocinolone Acetonide Intravitreal Implant in a real-world clinical setting. The trial met both of its co-primary endpoints at six months, demonstrating statistically significant improvements in best-corrected visual acuity (BCVA), a measure of vision, and reductions in central subfield thickness (CST), a marker of retinal swelling.
According to the data presented, these improvements were maintained through 24 months, a key secondary endpoint of the study.
The study's safety findings were consistent with previous clinical experience with the fluocinolone acetonide implant. The most commonly reported adverse events were similar to those observed in earlier trials of the treatment.
ILUVIEN is a sustained-release corticosteroid implant that delivers fluocinolone acetonide directly into the eye for up to 36 months. In the United States, it is approved for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye and diabetic macular edema in certain previously treated patients.
The implant is designed to provide long-term corticosteroid treatment directly inside the eye to help control inflammation associated with chronic uveitis and other retinal diseases.
ANI said the results add to the growing body of evidence supporting the use of the implant in patients with chronic NIU-PS, including those treated by retina specialists in routine clinical practice.
ANIP has traded in a 52-week range of $69.58 to $97.00. The stock closed Friday's trading (October 9, 2026) at $73.89, up 2.65%.
For comments and feedback contact: editorial@rttnews.com
Business News
Slide Shows
Biotech Stocks Facing FDA Decision In October 2026
Biotech Stocks Facing FDA Decision In September 2026
Biotech Stocks Facing FDA Decision In August 2026
Latest Updates on Middle East War
Sen. Murphy Says Hegseth Covering Up Cost And Damages Of Iran War
October 09, 2026 07:35 ET
Crude Oil Prices Moderately Higher After Yesterday's Spike
October 09, 2026 14:44 ET
U.S. Stocks Close Mostly Lower On Spike In Oil Prices, OpenAI Revenue Concerns
October 08, 2026 16:17 ET
U.S. Stocks Mostly Lower As Crude Oil Prices Spike
October 08, 2026 11:19 ET
Renewed Spike In Crude Oil Prices May Weigh On Wall Street
October 08, 2026 08:50 ET
View More
The minutes of the latest Federal Reserve policy session was the highlight this week which saw relatively less news on the economics front in the U.S. Latest trade data and survey results on the priva
October 09, 2026 15:35 ET
The minutes of the latest Federal Reserve policy session was the highlight this week which saw relatively less news on the economics front in the U.S. Latest trade data and survey results on the private sector also gained attention. In Europe, results of the purchasing managers’ survey were in focus, while the Reserve Bank of India policy announcement took the center stage in Asia.
View More Videos
RELATED NEWS
ANI Pharmaceuticals Wins FDA Approval For Generic Everolimus Tablets For Oral Suspension
FDA Approves ANI Pharma's Generic Everolimus Tablets
ANI Pharmaceuticals, Inc. Profit Climbs In Q2
ANI Pharmaceuticals Reports Positive Six-Month Data In Uveitis Trial
ANI Pharma Reports Positive Phase 4 Data For Fluocinolone Acetonide Implant In Chronic Uveitis
Latest Updates on COVID-19
View More
Editor's Pick
Most Read
Most Emailed
Delta Stock Drops On Cautious Earnings View In Q4 & FY26 After Weak Q3
October 09, 2026 09:40 ET
Nvidia-backed Australian AI Firm Firmus Scraps IPO Over Market Conditions
October 09, 2026 07:54 ET
American Airlines To Expand Starlink Connectivity To More Than 1000 Mainline Aircraft
October 08, 2026 11:57 ET
PepsiCo Q3 Profit Climbs, Core Margin Down; Updates FY26 View; Stock Gains
October 08, 2026 08:12 ET
Tesco Plc Stock Gains On H1 Profit Growth, FY27 Outlook Upgrade, Addl. Buyback
October 08, 2026 05:39 ET
Alimentation Couche-Tard To Buy Irving Oil Retail Assets In Québec, Ontario
October 09, 2026 10:19 ET
PepsiCo Q3 Profit Climbs, Core Margin Down; Updates FY26 View; Stock Gains
October 08, 2026 08:12 ET
Delta Stock Drops On Cautious Earnings View In Q4 & FY26 After Weak Q3
October 09, 2026 09:40 ET
Verizon, AT&T And T-Mobile Shares Plunge As SpaceX Strikes Spectrum Deal To Expand Starlink Mobile
October 09, 2026 17:32 ET
Nvidia-backed Australian AI Firm Firmus Scraps IPO Over Market Conditions
October 09, 2026 07:54 ET
Crescent Energy To Buy Devon's Eagle Ford Assets For $3.85 Bln; Launches $1 Bln Stock Offering
October 08, 2026 07:53 ET
DCC Energy Agrees To Sell Nexora To One Equity Partners For $725 Mln
October 09, 2026 02:30 ET
Hexagon To Buy Rocscience For $535 Mln
October 09, 2026 02:46 ET
Starbucks Explores Takeover Of Chipotle In Potential Record Restaurant Deal
October 08, 2026 17:01 ET
Fairfax Financial To Partner With Wittington To Acquire Boots Group
October 07, 2026 09:49 ET
Microchip Technology Acquires VORAGO Technologies For Undisclosed Sum
October 09, 2026 09:14 ET
Natera's Multi-cancer Early Detection Assay Granted Breakthrough Device Designation By FDA
October 09, 2026 08:17 ET
Netflix Reportedly Plans To Lay Off 5% Of Its Workforce
October 09, 2026 11:17 ET
LG Electronics Q3 Prelim. Operating Income, Revenues Rise; Stock Drops
October 07, 2026 00:57 ET
Teva Pharmaceutical Stock Rises 6% After FDA Approves Monthly Schizophrenia Treatment
October 09, 2026 11:24 ET
Waystream Group Q3 Sales Increase
October 07, 2026 01:14 ET
Alignment Healthcare Stock Falls 17% On 2027 Medicare Star Ratings
October 09, 2026 11:26 ET
Intact Financial Projects Total Pre-tax Catastrophe Losses Of About C$660 Mln In Q3
October 07, 2026 01:15 ET
Toro Slips To Loss In Q2, Shares Down By Over 14%
October 09, 2026 12:02 ET
Ballard Secures 4.8MW Order From Siemens Mobility To Power Romanian Hydrogen Trains
October 07, 2026 01:39 ET
VEON's Banglalink Launches Starlink Satellite-to-mobile In Bangladesh
October 09, 2026 12:12 ET
Lunnon Metals Notes BHP Deal To Sell Kambalda Nickel Concentrator To Gold Fields
October 07, 2026 01:43 ET
Avient Stock Falls 5% After Appointing Mike Frank As CEO
October 09, 2026 12:33 ET
Netcall PLC Profit Falls In Full Year
October 07, 2026 02:09 ET
Editors Pick
Delta Stock Drops On Cautious Earnings View In Q4 & FY26 After Weak Q3
October 09, 2026 09:40 ET
PepsiCo Q3 Profit Climbs, Core Margin Down; Updates FY26 View; Stock Gains
October 08, 2026 08:12 ET
Tesco Plc Stock Gains On H1 Profit Growth, FY27 Outlook Upgrade, Addl. Buyback
October 08, 2026 05:39 ET
Walmart Recalls Over 4.4 Mln Grill Brushes For Ingestion Risk
October 02, 2026 09:11 ET
Loading...
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
a0b43ced7b· 2026-10-12 20:02 · doubao / doubao-seed-evolving-latest-version · 策略包2226518bfdee当前